CDBIO(688739)2024-10-29 09:48Financial Performance - The company's operating revenue for Q3 2024 was ¥421,996,829.67, a decrease of 8.93% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥109,484,818.07, down 15.72% year-on-year[2] - The net profit after deducting non-recurring gains and losses was ¥101,267,649.75, reflecting a decline of 14.66% compared to the previous year[2] - Total operating revenue for the first three quarters of 2024 was CNY 1,302,689,599.82, a decrease of 2.4% compared to CNY 1,334,694,071.78 in the same period of 2023[15] - Net profit for the first three quarters of 2024 was CNY 329,698,128.04, down 29.0% from CNY 463,517,560.88 in the same period of 2023[16] - The company reported a total profit of CNY 405,162,196.94 for the first three quarters of 2024, down from CNY 552,054,087.78 in 2023[16] - Basic and diluted earnings per share for the first three quarters of 2024 were both CNY 0.80, down from CNY 1.11 in the same period of 2023[17] - The total profit for the first three quarters of 2024 was CNY 548,604,657.22, down 18.6% from CNY 673,606,546.98 in the same period of 2023[25] Research and Development - Research and development expenses totaled ¥113,306,418.64 in Q3 2024, representing 26.85% of operating revenue, an increase of 5.89 percentage points year-on-year[3] - Research and development expenses rose significantly to CNY 207,277,477.75, an increase of 48.9% compared to CNY 139,290,606.86 in 2023[15] - Research and development expenses increased significantly to CNY 123,849,598.01, up 44.7% from CNY 85,553,160.23 in the previous year[25] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period decreased by 34.19% due to increased expenditures on procurement and R&D[5] - Cash flow from operating activities generated a net amount of CNY 291,178,061.86, a decrease of 34.3% from CNY 442,469,509.15 in the previous year[18] - The net cash flow from operating activities was CNY 360,220,343.38, a decrease of 29.5% compared to CNY 511,248,562.42 in the first three quarters of 2023[27] - The company's cash and cash equivalents decreased to CNY 4,264,317,684.83 from CNY 4,547,961,783.28, reflecting a decline of approximately 6.24%[12][14] - The company's cash and cash equivalents decreased to approximately ¥4.26 billion from ¥4.54 billion, representing a decline of about 6.1%[21] - The net cash flow from investment activities was negative at approximately -¥192.45 million, an improvement compared to -¥1.79 billion in the previous period, indicating a reduction in cash outflow by about 89.2%[19] - The company reported a net cash outflow from investing activities of CNY -281,258,222.92, an improvement from CNY -1,832,368,263.24 in the previous year[27] Assets and Liabilities - Total assets at the end of Q3 2024 were ¥10,033,331,399.50, a slight decrease of 0.48% from the end of the previous year[3] - The total equity attributable to shareholders was ¥9,549,344,524.88, down 0.52% compared to the end of the previous year[3] - The total current liabilities rose to CNY 379,327,497.64 from CNY 356,785,829.13, indicating an increase of approximately 6.00%[13][14] - The company's total equity attributable to shareholders decreased to CNY 9,549,344,524.88 from CNY 9,599,129,239.76, a decline of about 0.52%[14] - The company's long-term equity investments decreased to CNY 104,147,251.69 from CNY 110,521,418.31, a decline of approximately 5.00%[12][14] - The total liabilities of the company rose to approximately ¥345.02 million from ¥330.56 million, an increase of about 4.4%[22] Shareholder Information - The company reported a total of 26,050 common shareholders at the end of the reporting period[6] - The top shareholder, Liaoning Chengda Biological Co., Ltd., held 54.67% of the shares, totaling 22,766.38 million shares[6] Other Financial Metrics - The weighted average return on net assets decreased by 0.20 percentage points to 1.15% in Q3 2024[3] - Tax expenses for the first three quarters of 2024 were CNY 75,464,068.90, a decrease from CNY 88,536,526.90 in the same period of 2023[16] - The company's financial expenses showed a decrease, with interest expenses at CNY 243,119.26 compared to CNY 276,108.21 in the previous year[25] - The company's sales revenue from goods and services received was CNY 1,213,054,527.77, down from CNY 1,254,158,851.29 in the same period of 2023[27]